- Investigator
- Tung T Wynn
- Status
- Accepting Candidates
Research at a glance
Top areas of exploration
- Hemophilia A , 4 publications
- Factor VIII , 3 publications
- Recombinant Proteins , 3 publications
- Hemostasis , 2 publications
Research activity
Active clinical trials
Pediatric cancer survivors are at an increased risk of excessive weight gain and reduced exercise behaviors with the potential for this risk to worsen over time. With over 80% of pediatric cancer patients living to adulthood, many pediatric cancer…
- Investigator
- Tung T Wynn
- Status
- Accepting Candidates
- Ages
- 5 Years - 14 Years
- Sexes
- All
- Investigator
- Tung T Wynn
- Status
- Accepting Candidates
My publications
Filter publications
18 publications
2020
Development and Validation of a Population-Pharmacokinetic Model for Rurioctacog Alfa Pegol (Adynovate®): A Report on Behalf of the WAPPS-Hemo Investigators Ad Hoc Subgroup.
Clinical pharmacokinetics
PubMed • Publisher's site2020
Primary pulmonary artery sarcoma in the pediatric patient: Review of literature and a case report.
Radiology case reports
PubMed • Publisher's site2019
Hemophilia Gene Therapy: New Development from Bench to Bed Side.
Current gene therapy
PubMed • Publisher's site2019
Perioperative haemostasis with full-length, PEGylated, recombinant factor VIII with extended half-life (rurioctocog alfa pegol) in patients with haemophilia A: Final results of a multicentre, single-arm phase III trial.
Haemophilia : the official journal of the World Federation of Hemophilia
PubMed • Publisher's site2016
Efficacy and safety of pegylated full-length recombinant factor VIII with extended half-life for perioperative haemostasis in haemophilia A patients.
Haemophilia : the official journal of the World Federation of Hemophilia
PubMed • Publisher's site